Ann M. Leen - 18 Jan 2022 Form 4 Insider Report for Allovir, Inc. (KLRS)

Role: Chief Scientific Officer
Signature: /s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol: KLRS
Transactions as of: 18 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2023, 16:00:29 UTC
Previous filing: 16 Nov 2021
Next filing: 17 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALVR	Common Stock	Award	$0	+23,256	+83%	$0.000000	51,256	18 Jan 2022	Direct	F1
transaction	ALVR	Common Stock	Award	$0	+14,000	+27%	$0.000000	65,256	01 Jul 2022	Direct	F2
transaction	ALVR	Common Stock	Award	$0	+43,750	+55%	$0.000000	124,006	02 Feb 2023	Direct	F3
holding	ALVR	Common Stock						2,288,154	18 Jan 2022	See footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALVR	Stock Option (Right to Buy)	Award	$0	+56,744	+18%	$0.000000	366,344	18 Jan 2022	Common Stock	56,744	$9.15	Direct	F5
transaction	ALVR	Stock Option (Right to Buy)	Award	$0	+26,000	+7.1%	$0.000000	392,344	01 Jul 2022	Common Stock	26,000	$4.13	Direct	F6
transaction	ALVR	Stock Option (Right to Buy)	Award	$0	+81,250	+21%	$0.000000	473,594	02 Feb 2023	Common Stock	81,250	$6.65	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F3	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
F4	Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5	25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F6	25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F7	25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.